Department of Biomedical Imaging, Genentech Inc., South San Francisco, California.
Siemens Medical Solutions USA, Inc. Mountain View, California.
Clin Cancer Res. 2018 Sep 15;24(18):4455-4467. doi: 10.1158/1078-0432.CCR-17-3262. Epub 2018 May 24.
The tumor microenvironment presents with altered extracellular matrix (ECM) and stroma composition, which may affect treatment efficacy and contribute to tissue stiffness. Ultrasound (US) elastography can visualize and quantify tissue stiffness noninvasively. However, the contributions of ECM and stromal components to stiffness are poorly understood. We therefore set out to quantify ECM and stroma density and their relation to tumor stiffness. A modified clinical ultrasound system was used to measure tumor stiffness and perfusion during tumor growth in preclinical tumor models. measurements were compared with collagen mass spectroscopy and automatic analysis of matrix and stromal markers derived from immunofluorescence images. US elastography estimates of tumor stiffness were positively correlated with tumor volume in collagen and myofibroblast-rich tumors, while no correlations were found for tumors with low collagen and myofibroblast content. US elastography measurements were strongly correlated with mechanical testing and mass spectroscopy-based measurements of total collagen and immature collagen crosslinks. Registration of ultrasound and confocal microscopy data showed strong correlations between blood vessel density and T-cell density in syngeneic tumors, while no correlations were found for genetic tumor models. In contrast to collagen density, which was positively correlated with stiffness, no significant correlations were observed for hyaluronic acid density. Finally, localized delivery of collagenase led to a significant reduction in tumor stiffness without changes in perfusion 24 hours after treatment. US elastography can be used as a potential biomarker to assess changes in the tumor microenvironment, particularly changes affecting the ECM. .
肿瘤微环境呈现出细胞外基质(ECM)和基质组成的改变,这可能影响治疗效果并导致组织硬度增加。超声弹性成像可以无创地可视化和量化组织硬度。然而,ECM 和基质成分对硬度的贡献还了解甚少。因此,我们旨在量化 ECM 和基质密度及其与肿瘤硬度的关系。使用改良的临床超声系统在临床前肿瘤模型中测量肿瘤生长过程中的肿瘤硬度和灌注。测量结果与胶原质谱法以及源自免疫荧光图像的基质和基质标志物的自动分析进行了比较。超声弹性成像估计的肿瘤硬度与富含胶原和成纤维细胞的肿瘤的肿瘤体积呈正相关,而胶原和成纤维细胞含量低的肿瘤则没有相关性。超声弹性成像测量值与机械测试和基于质谱法的总胶原和未成熟胶原交联的测量值具有很强的相关性。超声和共聚焦显微镜数据的配准显示,同种肿瘤中血管密度与 T 细胞密度之间存在很强的相关性,而遗传肿瘤模型则没有相关性。与与硬度呈正相关的胶原密度相比,透明质酸密度没有观察到显著相关性。最后,胶原酶的局部递送导致肿瘤硬度显著降低,而治疗 24 小时后灌注没有变化。超声弹性成像可用作评估肿瘤微环境变化的潜在生物标志物,特别是影响 ECM 的变化。